Effective Disease-Modifying Therapy for Allergic Rhinitis: Improving Patient Outcomes Through Allergen-specific Immunotherapy
Allergy/ Immunology
Curriculum:
Seasonal Allergens
Seasonal Allergens
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 27, 2017
April 27, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
The educational design of this activity addresses the needs of allergists, otolaryngologists, immunologists and other health care professionals involved in the treatment of patients with grass-pollen induced allergic rhinitis.
Relevant Terms:
Allergic rhinitis, asthma
Deborah A. Gentile, MD
Deborah A. Gentile, MD
Adjunct Professor of Medicine
Drexel University School of Medicine
Director of Allergy/Asthma Research
Division of Pulmonary, Allergy and Critical Care Medicine; Allegheny Health Network
Pittsburgh, Pennsylvania
Bio
Peter S. Creticos, MD
Peter Socrates Creticos, MD
Associate Professor of Medicine
Johns Hopkins School of Medicine – Division of Allergy & Clinical Immunology
Director of Clinical Research
Creticos Research Group, LLC
Baltimore, Maryland
Bio
Ayesha N. Khalid, MD, MBA
Ayesha N. Khalid, MD, MBA
Clinical Instructor
Harvard Medical School
Otolaryngologist (ENT) Surgeon
Cambridge Health Alliance
Concord, Massachusetts
Bio
| 1. | Conduct a complete patient interview and exam to establish history, triggers, lung health and a clinical diagnosis of allergic rhinitis | 2. | Perform allergy testing to establish a definitive trigger in patients with a clinical diagnosis of allergic rhinitis |
| 3. | Discuss evidence-based treatment approaches for patients who are mono- or polysensitized versus allergic to grasses and other allergens | 4. | Compare subcutaneous versus sublingual immunotherapy in terms of efficacy, safety, rates of systemic reactions and a patient's ability to adhere to the treatment course |
| 1. | Conduct a complete patient interview and exam to establish history, triggers, lung health and a clinical diagnosis of allergic rhinitis |
| 2. | Perform allergy testing to establish a definitive trigger in patients with a clinical diagnosis of allergic rhinitis |
| 3. | Discuss evidence-based treatment approaches for patients who are mono- or polysensitized versus allergic to grasses and other allergens |
| 4. | Compare subcutaneous versus sublingual immunotherapy in terms of efficacy, safety, rates of systemic reactions and a patient's ability to adhere to the treatment course |
Accreditor Disclosure of Conflicts of Interest Policy:
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Faculty or Presenter | Reported Financial Relationship |
| Peter Creticos, MD | Stallergenes Greer; Circassia; Allakos, Inc.; Anergis SA; Merck & Co., Inc.; WebMD LLC (Medscape) |
| Ayesha Khalid, MD | 480 Biomedical; Castle Creek Pharma; Stallergenes Greer; Patient Doctor Technologies, Inc. (Doctella); Abbott; Lungpacer Medical Inc. |
| Deborah Gentile, MD | Stallergenes Greer |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Planner or Manager | Reported Financial Relationship |
| Amanda Glazar, PhD | Nothing to disclose |
| Andrea Funk | Nothing to disclose |
| Laura Gilsdorf | Nothing to disclose |
| Chris Blagden, PhD | Nothing to disclose |
Accreditation Statement(s):
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Consultants in Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement(s):
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Consultants in Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions:
This language will change a bit since this is a RealCME platform activity – but you’ll be able to review it once it’s changed.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, and nurses are entitled to receive 1.00 CNE contact hours, all of which is pharmacology credit worthy. Statement of credit will be available to print from your user history page.
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians and nurses who successfully complete the post-test and evaluation will respectively receive CME or CNE. You must score with a 70% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Privacy Policy:
Global protects the privacy of personal and other information regarding participants, educational partners and joint sponsors. Global and our joint sponsors will not release personally identifiable information to a third party without the customer's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
